What's Hot

View all perspectives
      Mitochondria: the powerhouse of the cell—but the fuel behind gout flares?
      #ACR24 @RheumNow https://t.co/lV4dovLV18

      Akhil Sood MD AkhilSoodMD

      4 months 3 weeks ago
      Mitochondria: the powerhouse of the cell—but the fuel behind gout flares? #ACR24 @RheumNow https://t.co/lV4dovLV18
      #CRISPR reviewed in
      👇
      #fibroblasts

      Found deletion of certain genes
      Ex JIA had marked change in expression

      Yr in

      Janet Pope Janetbirdope

      4 months 3 weeks ago
      #CRISPR reviewed in 👇 #fibroblasts Found deletion of certain genes Ex JIA had marked change in expression Yr in Preview ACR24 @RheumNow @ACRheum Dr Chris Ritchlin 👏 https://t.co/jnmtk1eXGp
      Mortality Risk After Stopping Glucocorticosteroids (GC) in RA.
      In a study of 28,078 RA patients:
      Mortality risk from CVD

      Antoni Chan MD (Prof) synovialjoints

      4 months 3 weeks ago
      Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E
      Did you know? 🤔
      Capillaroscopy is performed on the nailfold because it is the area where the capillaries are fully vi

      sheila RHEUMarampa

      4 months 3 weeks ago
      Did you know? 🤔 Capillaroscopy is performed on the nailfold because it is the area where the capillaries are fully visualized compared to the skin where capillary tips are only seen. This capillaroscopy session with Dr. Cutolo is so high yield I'd say! 🤓 @RheumNow #ACR24 https://t.co/8AN7RXUDrM
      #Poorer responses to #Rx in
      #Females vs #males

      Sex hormone and pathway differences
      explained
      👇
      Biological differe

      Janet Pope Janetbirdope

      4 months 3 weeks ago
      #Poorer responses to #Rx in #Females vs #males Sex hormone and pathway differences explained 👇 Biological differences F start worse in disease activity F May have ⬇️ response to #Rx Yr in Preview C Ritchlin @lihi_eder’s PsA work quoted ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL
      VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA.
      RA patients vaccinated with PCV13

      Antoni Chan MD (Prof) synovialjoints

      4 months 3 weeks ago
      VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA. RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month: 88% (ELISA) vs. 75% 96% (OPA) vs. 88% At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG
      Hydralazine - known culprit of drug-induced AAV

      How does hydral (H) AAV differ from primary (1) AAV?
      💥 High dual pos

      Brian Jaros, MD Dr_Brian_MD

      4 months 3 weeks ago
      Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496
      Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropos

      Richard Conway RichardPAConway

      4 months 3 weeks ago
      Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr
      Severe thrombocytopenia (TP) is rare but linked to major organ involvement and poor prognosis in #SLE. Data from the RIS

      Bella Mehta bella_mehta

      4 months 3 weeks ago
      Severe thrombocytopenia (TP) is rare but linked to major organ involvement and poor prognosis in #SLE. Data from the RISE registry shows TP in 9.3% of SLE patients, with higher prevalence in males, African-Americans+ those with multiple comorbidities. #ACR24 @RheumNow abst#2680
      In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had sign

      sheila RHEUMarampa

      4 months 3 weeks ago
      In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity. Mechanism? NAC reduces rapamycin (mTOR) activation. Common AEs: nausea, vomiting @RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP
      Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA

      Richard Conway RichardPAConway

      4 months 3 weeks ago
      Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs
      In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA a

      Jiha Lee JihaRheum

      4 months 3 weeks ago
      In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe
      Difficult to Manage Axial Spondyloarthritis

      Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily

      Dr. John Cush RheumNow

      4 months 3 weeks ago
      Difficult to Manage Axial Spondyloarthritis Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain, stiffness, and reduced mobility. #ACR24 https://t.co/5i5QtJJm16 https://t.co/c4bllA8ngJ
      RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All co

      Dr. John Cush RheumNow

      4 months 3 weeks ago
      RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
      SELECT-GCA suggests JAKis may be the new kid on the block

      Clinicians treating giant cell arteritis (GCA) have long had

      Dr. John Cush RheumNow

      4 months 3 weeks ago
      SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY

      Podcasts

      • An Epidural Letdown (4.4.2025)
      • Biomarkers in RA
      • Cancer Survival with TNF Inhibitors (3.28.2025)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      ×